Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-18-006188
Filing Date
2018-08-02
Accepted
2018-08-02 13:44:32
Documents
73
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q clvs-20180630x10q.htm 10-Q 2171023
2 EX-10.19 clvs-20180630ex10195d2f6.htm EX-10.19 85335
3 EX-21.1 clvs-20180630ex211086ebb.htm EX-21.1 13081
4 EX-31.1 clvs-20180630ex311574da5.htm EX-31.1 19887
5 EX-31.2 clvs-20180630ex312fc9244.htm EX-31.2 20127
6 EX-32.1 clvs-20180630ex3210cf089.htm EX-32.1 8001
7 EX-32.2 clvs-20180630ex3228c32e2.htm EX-32.2 8382
  Complete submission text file 0001558370-18-006188.txt   8583476

Data Files

Seq Description Document Type Size
8 EX-101.INS clvs-20180630.xml EX-101.INS 2128095
9 EX-101.SCH clvs-20180630.xsd EX-101.SCH 44293
10 EX-101.CAL clvs-20180630_cal.xml EX-101.CAL 61846
11 EX-101.DEF clvs-20180630_def.xml EX-101.DEF 149135
12 EX-101.LAB clvs-20180630_lab.xml EX-101.LAB 457441
13 EX-101.PRE clvs-20180630_pre.xml EX-101.PRE 319463
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

EIN.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35347 | Film No.: 18987591
SIC: 2834 Pharmaceutical Preparations